Phase Ⅰ/Ⅱ study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patie

• 作 者: Cerchietti LC Bonomi MR Navigante AH Castro MA Cabalar ME Roth BM
• 机 构: Translational Research Unit Universidad de Buenos Aires Argentina,Translational Research Unit Univer
• 出 处: 中国神经肿瘤杂志
• 发表日期: 2005年01期
• 关键词: celecoxib radiotherapy metastases concomitant Celecoxib Phase measurable cycloox

Purpose:The primary goal of this phase I/II study was to evaluate the feasibility, safety and efficacy of celecoxib administered concomitant to radiotherapy to treat unresectable BM. Patients and methods: Patients with measurable BM by CT or MRI, unresectability criteria by a neurosurgeon and RPA-RTOG class II were eligible. Celecoxib was administered at 400 mg/day during the entire course of radiotherapy. All patients were irradiated with 60Co beams to whole-brain dose of 32 Gy (20 fractions

Purpose: The primary goal of this phase I / II study was to evaluate the feasibility, safety and efficacy of celecoxib administered concomitant to radiotherapy to treat unresectable BM. Patients and methods: Patients with measurable BM by CT or MRI, unresectability criteria by a neurosurgeon All patients were irradiated with 60Co beams to whole-brain dose of 32 Gy (20 fractions